https://www.pharmaradar360.com/article/tadekinig-alfa-a051011f4703cdc6Pharma Surgeen2026-07-30T15:30:00.000ZTadekinig alfaの米国におけるオプション権行使のお知らせhttps://www.pharmaradar360.com/article/pharma-pulse-infinitus-ai-hub-play-eversana-s-cell-therapy-partnership-cold-chai-aeb20a5dac9e856ePharma Surgeen2026-07-30T15:01:14.000ZPharma Pulse: Infinitus' AI Hub Play, EVERSANA's Cell Therapy Partnership, Cold Chain Dealshttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-30T14:30:09.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-30T14:30:09.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/so-can-i-get-this-peptide-the-loophole-making-way-for-the-us-s-wild-west-of-unte-46ade855ec6c0d7dPharma Surgeen2026-07-30T14:23:00.000Z‘So ... can I get this peptide?’: the loophole making way for the US’s ‘wild west’ of untested drugshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-1-0a74a6b27292da2aPharma Surgeen2026-07-30T14:20:22.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.13, Implies 8% Upsidehttps://www.pharmaradar360.com/article/australia-approves-first-in-class-niktimvo-for-later-line-cgvhd-5876454f27c3c212Pharma Surgeen2026-07-30T14:10:53.000ZAustralia approves first-in-class Niktimvo for later-line cGVHDhttps://www.pharmaradar360.com/article/national-partnership-agreement-on-asylum-seeker-health-in-england-a7f2599358415303Pharma Surgeen2026-07-30T14:00:02.000ZNational partnership agreement on asylum seeker health in Englandhttps://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3Pharma Surgeen2026-07-30T14:00:02.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/greenberg-traurig-advises-entera-bio-in-record-275m-israeli-biotech-pipe-e06869d115e09589Pharma Surgeen2026-07-30T13:48:44.000ZGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEhttps://www.pharmaradar360.com/article/gsk-pens-110m-biological-datasets-pact-with-ai-biotech-relation-adefe9e9df13bed4Pharma Surgeen2026-07-30T13:46:54.000ZGSK pens $110M biological datasets pact with AI biotech Relationhttps://www.pharmaradar360.com/article/pharmacy-inside-jobs-sports-pharmacist-9877f234993a94c7Pharma Surgeen2026-07-30T13:44:00.000ZPharmacy Inside Jobs : sports pharmacisthttps://www.pharmaradar360.com/article/recordati-publication-of-the-interim-report-first-half-as-at-30-06-2026-6a35e40675f455d6Pharma Surgeen2026-07-30T13:42:09.000ZRECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2026)https://www.pharmaradar360.com/article/boston-scientific-cuts-guidance-again-after-unveiling-restructuring-plan-4bb3180d9a19e55bPharma Surgeen2026-07-30T13:33:27.000ZBoston Scientific cuts guidance again after unveiling restructuring planhttps://www.pharmaradar360.com/article/ember-alfresa-strike-japan-cold-chain-alliance-58ab4c595f625835Pharma Surgeen2026-07-30T13:26:14.000ZEmber, Alfresa Strike Japan Cold Chain Alliancehttps://www.pharmaradar360.com/article/regulations-are-being-implemented-fda-commissioner-tukaram-munde-on-statewide-fo-da12491db0bb9340Pharma Surgeen2026-07-30T13:21:22.000ZRegulations Are Being Implemented: FDA Commissioner Tukaram Munde On Statewide Food Safety Drive - VIDEOhttps://www.pharmaradar360.com/article/ember-lifesciences-wins-alfresa-backing-for-japan-cold-chain-push-6c165a841a5e6230Pharma Surgeen2026-07-30T13:17:50.000ZEmber LifeSciences wins Alfresa backing for Japan cold chain pushhttps://www.pharmaradar360.com/article/nhs-and-industry-join-forces-on-next-generation-of-hospitals-35ccd7191fb21b0fPharma Surgeen2026-07-30T13:13:27.000ZNHS AND INDUSTRY JOIN FORCES ON NEXT GENERATION OF HOSPITALShttps://www.pharmaradar360.com/article/cingulate-publishes-phase-3-adhd-drug-trial-results-in-journal-e7c602eea1a88265Pharma Surgeen2026-07-30T13:08:09.000ZCingulate publishes phase 3 ADHD drug trial results in journalhttps://www.pharmaradar360.com/article/imunon-reports-strong-enrollment-momentum-in-phase-3-ovation-3-trial-of-imnn-001-7a9a201434fbdf9fPharma Surgeen2026-07-30T13:07:37.000ZIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancerhttps://www.pharmaradar360.com/article/what-s-next-for-direct-to-patient-091981349bbbf0bePharma Surgeen2026-07-30T13:06:14.000ZWhat's Next for Direct-to-Patient?https://www.pharmaradar360.com/article/mhra-safety-roundup-july-2026-b94269bf7f34dce3Pharma Surgeen2026-07-30T13:03:00.000ZMHRA Safety Roundup: July 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-30T13:00:02.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69Pharma Surgeen2026-07-30T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season-d6b3a2494c57cfa7Pharma Surgeen2026-07-30T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-30T13:00:02.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-30T13:00:02.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-measles-guidelines-19fe295025dcfc04Pharma Surgeen2026-07-30T13:00:02.000ZNational measles guidelineshttps://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-30T13:00:02.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-30T13:00:02.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-30T13:00:02.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-30T13:00:02.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/attovia-braveheart-and-vogenx-seek-more-than-500m-across-trio-of-ipos-5a14db69e13a11efPharma Surgeen2026-07-30T12:57:43.000ZAttovia, Braveheart and Vogenx seek more than $500M across trio of IPOshttps://www.pharmaradar360.com/article/will-generic-drug-tariffs-impact-pharma-etfs-308818d988283d90Pharma Surgeen2026-07-30T12:53:00.000ZWill Generic Drug Tariffs Impact Pharma ETFs?https://www.pharmaradar360.com/article/hk-restates-support-for-cell-and-gene-therapy-amid-biotech-push-08393485127236baPharma Surgeen2026-07-30T12:49:42.000ZHK restates support for cell and gene therapy amid biotech pushhttps://www.pharmaradar360.com/article/cingulate-announces-publication-of-phase-3-adhd-trial-results-in-journal-of-chil-a4b26e319595bd6cPharma Surgeen2026-07-30T12:45:37.000ZCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacologyhttps://www.pharmaradar360.com/article/sellas-life-sciences-clinical-biopharmaceutical-company-0899336d73776e11Pharma Surgeen2026-07-30T12:45:02.000ZSELLAS Life Sciences - Clinical Biopharmaceutical Companyhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-eb15919be77b9b35Pharma Surgeen2026-07-30T12:44:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-b033ea854c7d902fPharma Surgeen2026-07-30T12:39:00.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/india-takes-action-against-90-pct-of-inspected-high-risk-pharmaceutical-faciliti-a544b4a7d578cc34Pharma Surgeen2026-07-30T12:38:55.000ZIndia takes action against 90 pct of inspected high-risk pharmaceutical facilitieshttps://www.pharmaradar360.com/article/leading-oncology-journal-accepts-for-publication-new-cel-sci-multikine-phase-3-d-d8205ff711bcdcc3Pharma Surgeen2026-07-30T12:31:00.000ZLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patientshttps://www.pharmaradar360.com/article/cingulate-s-adhd-candidate-improved-scores-at-all-three-doses-6dd1981e0bfc7c73Pharma Surgeen2026-07-30T12:30:00.000ZCingulate's ADHD candidate improved scores at all three doseshttps://www.pharmaradar360.com/article/mmi-receives-fda-approval-to-advance-to-phase-ii-of-patient-enrollment-in-ground-570a69cfeaabc312Pharma Surgeen2026-07-30T12:24:45.000ZMMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patientshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-q2-earnings-call-highlights-edacb5d353369133Pharma Surgeen2026-07-30T12:22:30.000ZTeva Pharmaceutical Industries Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/germany-apax-to-carve-out-two-market-leading-pharmaceutical-packaging-businesses-e6de6520446bce83Pharma Surgeen2026-07-30T12:13:50.000ZGermany: Apax to carve out two market-leading pharmaceutical packaging businesses from Gerresheimerhttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-teva-a-bargain-after-results-and-higher-revenu-3e6f9c195f430ed5Pharma Surgeen2026-07-30T12:08:17.000ZIs Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?https://www.pharmaradar360.com/article/bombay-hc-tells-fda-to-focus-on-serious-food-safety-violations-not-minor-infract-eb095cc998a47e04Pharma Surgeen2026-07-30T12:06:22.000ZBombay HC Tells FDA to Focus on Serious Food Safety Violations, Not Minor Infractionshttps://www.pharmaradar360.com/article/how-biotech-steadies-beauty-s-ingredient-supply-chain-challenges-9d93c60ad7674355Pharma Surgeen2026-07-30T12:06:13.000ZHow biotech steadies beauty’s ingredient supply chain challengeshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-q1-earnings-call-highlights-e91895cb129ad3f1Pharma Surgeen2026-07-30T12:03:52.000ZTakeda Pharmaceutical Q1 Earnings Call Highlightshttps://www.pharmaradar360.com/article/a16z-backed-biotech-braveheart-seeks-318-8-million-in-us-ipo-7fab0dbf1b1a1f09Pharma Surgeen2026-07-30T12:02:53.000ZA16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPOhttps://www.pharmaradar360.com/article/masschallenge-targets-israel-taiwan-for-biotech-medtech-accelerator-cbf5cf2bd97d609aPharma Surgeen2026-07-30T12:00:00.000ZMassChallenge targets Israel, Taiwan for biotech, medtech acceleratorhttps://www.pharmaradar360.com/article/juvederm-day-returns-to-u-s-on-august-19-42341076202d1d14Pharma Surgeen2026-07-30T12:00:00.000ZJUVÉDERM® Day Returns to U.S. on August 19https://www.pharmaradar360.com/article/calls-for-collaboration-on-medical-research-in-wales-5702457c03e31897Pharma Surgeen2026-07-30T11:51:40.000ZCalls for collaboration on medical research in Waleshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-q1-results-met-expectations-with-pipeline-launches-940fb84d4b42b771Pharma Surgeen2026-07-30T11:50:14.000ZTakeda Pharmaceutical Company: Q1 results met expectations, with pipeline launches set to drive future growthhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-legend-biotech-stock-at-65-0fa4bd2370a724c7Pharma Surgeen2026-07-30T11:42:00.000ZH.C. Wainwright reiterates Buy on Legend Biotech stock at $65https://www.pharmaradar360.com/article/judge-says-the-fda-never-explained-why-mifepristone-prescriber-certification-was-5b32e5ffb978080fPharma Surgeen2026-07-30T11:31:30.000ZJudge Says the FDA Never Explained Why Mifepristone Prescriber Certification Was Necessaryhttps://www.pharmaradar360.com/article/mers-cov-self-isolating-awaiting-mers-cov-test-result-4d7d31f88904d305Pharma Surgeen2026-07-30T11:25:24.000ZMERS-CoV: self-isolating awaiting MERS-CoV test resulthttps://www.pharmaradar360.com/article/alterity-s-ath434-trial-for-rare-msa-may-enroll-200-patients-32b326c49ec08f32Pharma Surgeen2026-07-30T11:25:00.000ZAlterity’s ATH434 Trial for Rare MSA May Enroll 200 Patientshttps://www.pharmaradar360.com/article/eyepoint-completes-enrollment-of-both-pivotal-phase-3-trials-of-duravyutm-for-tr-fb79ba0be55461b9Pharma Surgeen2026-07-30T11:20:48.000ZEyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)https://www.pharmaradar360.com/article/espana-pais-pionero-en-la-union-europea-en-la-supresion-del-prospecto-en-papel-e-9a354c735ec11ff8Pharma Surgeen2026-07-30T11:17:41.000ZEspaña, país pionero en la Unión Europea en la supresión del prospecto en papel en medicamentos de ámbito hospitalariohttps://www.pharmaradar360.com/article/us-high-growth-tech-stocks-to-watch-in-july-2026-5aa3966fdc5007edPharma Surgeen2026-07-30T11:15:03.000ZUS High Growth Tech Stocks To Watch In July 2026https://www.pharmaradar360.com/article/terahertz-spectroscopy-and-machine-learning-accelerate-api-analysis-8b9b4492a18fcec4Pharma Surgeen2026-07-30T11:14:32.000ZTerahertz spectroscopy and machine learning accelerate API analysishttps://www.pharmaradar360.com/article/guidance-magnetic-resonance-imaging-equipment-in-clinical-use-safety-guidelines-3b11947531275490Pharma Surgeen2026-07-30T11:13:47.000ZGuidance: Magnetic resonance imaging equipment in clinical use: safety guidelineshttps://www.pharmaradar360.com/article/eyepoint-inc-nasdaq-eypt-finishes-phase-3-dme-enrollment-sets-2027-data-goal-3ccc455cede9f057Pharma Surgeen2026-07-30T11:05:49.000ZEyePoint, Inc. (Nasdaq: EYPT) finishes Phase 3 DME enrollment, sets 2027 data goalhttps://www.pharmaradar360.com/article/bristol-myers-squibb-reports-second-quarter-financial-results-for-2026-c3f223e49e5e4205Pharma Surgeen2026-07-30T10:59:00.000ZBristol Myers Squibb Reports Second Quarter Financial Results for 2026https://www.pharmaradar360.com/article/india-takes-action-against-90-of-inspected-high-risk-pharmaceutical-facilities-r-5bb5b9d28cedadacPharma Surgeen2026-07-30T10:50:53.000ZIndia takes action against 90% of inspected high-risk pharmaceutical facilities, regulator sayshttps://www.pharmaradar360.com/article/panda-biotech-culturewell-launch-india-s-first-hemp-yarn-supply-chain-90e8c55886471832Pharma Surgeen2026-07-30T10:49:40.000ZPanda Biotech, Culturewell launch India’s first hemp yarn supply chainhttps://www.pharmaradar360.com/article/india-takes-action-against-90-of-inspected-high-risk-pharmaceutical-facilities-r-b7a083b58e45a649Pharma Surgeen2026-07-30T10:46:19.000ZIndia takes action against 90% of inspected high-risk pharmaceutical facilities, regulator sayshttps://www.pharmaradar360.com/article/tri-locum-partners-lp-has-30-75-million-position-in-teva-pharmaceutical-industri-39b88b9dc6a12b90Pharma Surgeen2026-07-30T10:46:05.000ZTri Locum Partners LP Has $30.75 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pfizer-s-litfulo-studies-showed-more-facial-and-body-repigmentation-f4bcd1c9d1a48bc5Pharma Surgeen2026-07-30T10:45:00.000ZPfizer's LITFULO studies showed more facial and body repigmentationhttps://www.pharmaradar360.com/article/j-j-wagers-on-next-cell-therapy-frontier-with-2-6bn-sail-bio-acquisition-option-7ddb46ebf70351c1Pharma Surgeen2026-07-30T10:41:15.000ZJ&J wagers on next cell therapy frontier with $2.6bn Sail Bio acquisition optionhttps://www.pharmaradar360.com/article/adcom-expected-for-uniqure-s-huntington-s-gene-therapy-chief-medical-officer-say-d69190bfbe03c1d8Pharma Surgeen2026-07-30T10:40:51.000ZAdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer sayshttps://www.pharmaradar360.com/article/the-1-2tn-untapped-pharma-opportunity-in-tropical-conservation-f1a89d87c5084007Pharma Surgeen2026-07-30T10:40:51.000ZThe $1.2tn untapped pharma opportunity in tropical conservationhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-unit-enters-fx-swap-and-fx-forward-contracts-with-icbc-219e8bc3d5160d70Pharma Surgeen2026-07-30T10:38:57.000ZCSPC Pharmaceutical Says Unit Enters FX Swap And FX Forward Contracts With ICBC Since June 16https://www.pharmaradar360.com/article/legionnaires-disease-national-surveillance-scheme-c6b5eec941da2352Pharma Surgeen2026-07-30T10:35:56.000ZLegionnaires' disease: national surveillance schemehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-2027-q1-results-earnings-call-presentation-f0aa4656290af3ffPharma Surgeen2026-07-30T10:34:32.000ZTakeda Pharmaceutical Company Limited 2027 Q1 - Results - Earnings Call Presentation (NYSE:TAK) 2026-07-30https://www.pharmaradar360.com/article/fda-suspends-licences-of-21-pune-food-outlets-seizes-goods-worth-rs-50-65-lakh-ffdcfe8519dba9dcPharma Surgeen2026-07-30T10:34:11.000ZFDA suspends licences of 21 Pune food outlets, seizes goods worth Rs 50.65 lakhhttps://www.pharmaradar360.com/article/families-gather-at-state-capitol-to-mark-prescribed-harm-awareness-day-6ca8a37da4acdb9aPharma Surgeen2026-07-30T10:29:30.000ZFamilies gather at state capitol to mark Prescribed Harm Awareness Dayhttps://www.pharmaradar360.com/article/portage-biotech-alp-stock-trends-and-sentiment-2026-alp-30e8051ee934e3faPharma Surgeen2026-07-30T10:12:07.000ZPortage Biotech (ALP) Stock Trends and Sentiment 2026 $ALPhttps://www.pharmaradar360.com/article/when-foreign-investments-in-pharma-and-biotech-become-a-national-security-concer-f26386bda2965018Pharma Surgeen2026-07-30T10:06:55.000ZWhen Foreign Investments in Pharma and Biotech Become a National Security Concernhttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-outlines-fda-backed-phase-3-plan-for-ath434-745447facf69e726Pharma Surgeen2026-07-30T10:05:21.000ZAlterity Therapeutics (NASDAQ: ATHE) outlines FDA-backed Phase 3 plan for ATH434https://www.pharmaradar360.com/article/takeda-pharmaceutical-nyse-tak-q1-2026-revenue-1-22t-eps-71-65-2bee652264979825Pharma Surgeen2026-07-30T10:05:10.000ZTakeda Pharmaceutical (NYSE: TAK) Q1 2026 revenue ¥1.22T, EPS ¥71.65https://www.pharmaradar360.com/article/sharp-rise-in-cyclospora-infections-linked-to-mexico-travel-6e286df30d5ba91bPharma Surgeen2026-07-30T10:00:00.000ZSharp rise in cyclospora infections linked to Mexico travelhttps://www.pharmaradar360.com/article/amneal-reports-second-quarter-2026-financial-results-af07df3365c7afc1Pharma Surgeen2026-07-30T10:00:00.000ZAmneal Reports Second Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/181-294-shares-in-teva-pharmaceutical-industries-ltd-teva-acquired-by-healthcare-d7284f5efdf23c9ePharma Surgeen2026-07-30T09:46:11.000Z181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fundhttps://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-with-every-discovery-5e1561178cecd539Pharma Surgeen2026-07-30T09:32:41.000ZOno Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientisthttps://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-7dcdc96aed7a0d00Pharma Surgeen2026-07-30T09:30:00.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/j-j-pays-sail-785m-charting-course-to-possible-in-vivo-car-t-buyout-7e8cdec0ea5682d4Pharma Surgeen2026-07-30T09:29:11.000ZJ&J pays Sail $785M, charting course to possible in vivo CAR-T buyouthttps://www.pharmaradar360.com/article/study-protecting-tropical-forests-could-save-pharmaceutical-industry-up-to-1-2tr-2a97d26f780a7f2aPharma Surgeen2026-07-30T09:20:58.000ZStudy: Protecting tropical forests could save pharmaceutical industry up to $1.2trhttps://www.pharmaradar360.com/article/mumbai-food-safety-crackdown-every-licence-suspended-since-tukaram-mundhe-took-c-6bff75affeb8d749Pharma Surgeen2026-07-30T09:20:00.000ZMumbai food safety crackdown: Every licence suspended since Tukaram Mundhe took charge as FDA chiefhttps://www.pharmaradar360.com/article/ukhsa-report-shows-2-877-excess-deaths-caused-by-may-and-june-heatwaves-87b94de79fef5d1ePharma Surgeen2026-07-30T09:08:34.000ZUKHSA report shows 2,877 excess deaths caused by May and June heatwaveshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-for-older-adults-b709407e14b34df9Pharma Surgeen2026-07-30T09:01:25.000ZRespiratory syncytial virus (RSV): vaccination for older adultshttps://www.pharmaradar360.com/article/using-the-professional-title-nurse-17092dc6e135d308Pharma Surgeen2026-07-30T09:00:05.000ZUsing the professional title ‘nurse’https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-30T08:58:55.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-anik-che-rise-with-q2-results-icui-nbix-rprx-27ccdfdd80a125b9Pharma Surgeen2026-07-30T08:53:00.000ZBiotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRXhttps://www.pharmaradar360.com/article/maharashtra-fda-staff-allege-double-shifts-severe-work-pressure-amid-staff-short-86956cd7872be855Pharma Surgeen2026-07-30T08:39:43.000ZMaharashtra FDA Staff Allege Double Shifts, Severe Work Pressure Amid Staff Shortagehttps://www.pharmaradar360.com/article/principal-financial-group-inc-decreases-holdings-in-teva-pharmaceutical-industri-f0c7609b279ab669Pharma Surgeen2026-07-30T08:37:43.000ZPrincipal Financial Group Inc. Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-raises-revenue-guidance-is-the-15-undervalua-2edba534d77c89a2Pharma Surgeen2026-07-30T08:36:25.000ZTeva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?https://www.pharmaradar360.com/article/some-more-notes-on-pharmaceutical-tariffs-61d63400b95246b4Pharma Surgeen2026-07-30T08:35:00.000ZSome More Notes On Pharmaceutical Tariffshttps://www.pharmaradar360.com/article/u-s-dependence-on-china-is-a-national-security-risk-bdad282a651ec92fPharma Surgeen2026-07-30T08:30:25.000ZU.S. dependence on China is a national security riskhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-30T08:30:21.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153Pharma Surgeen2026-07-30T08:30:16.000ZNational norovirus and rotavirus surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/ukhsa-ad-hoc-statistical-publications-3cbe759f572dbfdcPharma Surgeen2026-07-30T08:30:15.000ZUKHSA ad hoc statistical publicationshttps://www.pharmaradar360.com/article/interim-heat-mortality-monitoring-report-england-may-and-june-2026-a051d1a7af9c587cPharma Surgeen2026-07-30T08:30:14.000ZInterim heat mortality monitoring report, England: May and June 2026https://www.pharmaradar360.com/article/pre-release-access-lists-tuberculosis-in-england-national-quarterly-reports-8f126ee050dac709Pharma Surgeen2026-07-30T08:30:13.000ZPre-release access lists: Tuberculosis in England national quarterly reportshttps://www.pharmaradar360.com/article/pre-release-access-list-reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surve-f8f3de78c8bebefaPharma Surgeen2026-07-30T08:30:13.000ZPre-release access list: Reports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2024https://www.pharmaradar360.com/article/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2026-1bfcb2c59c9cd8a7Pharma Surgeen2026-07-30T08:30:13.000ZMeasles, mumps and rubella: lab-confirmed cases in England 2026https://www.pharmaradar360.com/article/haemophilus-influenzae-lab-reports-by-age-group-and-serotype-99bef29f7847333aPharma Surgeen2026-07-30T08:30:13.000ZHaemophilus influenzae: lab reports by age group and serotypehttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-reports-8174ab5932d8ff62Pharma Surgeen2026-07-30T08:30:09.000ZTuberculosis in England: national quarterly reportshttps://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-df1cab884cded473Pharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems, 2000 to 2025https://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-8d544b87c4e3a12aPharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems: 2000 to 2024https://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66fPharma Surgeen2026-07-30T08:30:09.000ZMycoplasma genitalium antimicrobial resistance surveillance (MARS)https://www.pharmaradar360.com/article/tuberculosis-tb-diagnosis-screening-management-and-data-ace9722645b7304dPharma Surgeen2026-07-30T08:30:09.000ZTuberculosis (TB): diagnosis, screening, management and datahttps://www.pharmaradar360.com/article/pertussis-immunisation-in-pregnancy-vaccine-coverage-england-d2e1f6887adda4f0Pharma Surgeen2026-07-30T08:30:08.000ZPertussis immunisation in pregnancy: vaccine coverage (England)https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-21-food-establishments-across-pune-division-e02dd840f87000ddPharma Surgeen2026-07-30T08:29:13.000ZPune: FDA Suspends Licences of 21 Food Establishments Across Pune Divisionhttps://www.pharmaradar360.com/article/chong-kun-dang-bio-gains-fda-trial-approval-f1a3e487dc1718cePharma Surgeen2026-07-30T08:23:45.000ZChong Kun Dang Bio Gains FDA Trial Approvalhttps://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-cf9e28d146e3c0ecPharma Surgeen2026-07-30T08:21:25.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-62e98adcc67319b8Pharma Surgeen2026-07-30T08:19:39.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-055d0ff39f0aca89Pharma Surgeen2026-07-30T08:19:35.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/masschallenge-launches-breakthrough-bio-to-catapult-international-biotech-and-me-60ae51b773c0c700Pharma Surgeen2026-07-30T08:11:01.000ZMassChallenge Launches Breakthrough Bio to Catapult International Biotech and Medtech Start-ups in the U.S. Markethttps://www.pharmaradar360.com/article/krystal-biotech-krys-could-be-40-overvalued-as-kb801-news-tests-its-price-ced2ebb44249f5dfPharma Surgeen2026-07-30T08:07:55.000ZKrystal Biotech (KRYS) Could Be 40% Overvalued As KB801 News Tests Its Pricehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-profit-drops-9-in-fiscal-q1-0b40fe1c3b94f101Pharma Surgeen2026-07-30T08:01:39.000ZTakeda Pharmaceutical Profit Drops 9% in Fiscal Q1https://www.pharmaradar360.com/article/takeda-pharmaceutical-fiscal-q1-core-earnings-revenue-rise-a17535fb7bcb9187Pharma Surgeen2026-07-30T07:46:40.000ZTakeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Risehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-reaffirms-earnings-guidance-for-the-fiscal-8055febee8b73041Pharma Surgeen2026-07-30T07:35:42.000ZTakeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2026https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-21-food-establishments-seizes-50-65-lakh-worth-of-83f8e265a470d0d3Pharma Surgeen2026-07-30T07:34:06.000ZPune: FDA Suspends Licences Of 21 Food Establishments, Seizes ₹50.65 Lakh Worth Of Suspected Adulteratedhttps://www.pharmaradar360.com/article/a-maternal-gbs-vaccine-just-cleared-phase-1-2-here-s-what-the-trial-design-tells-ae32d90cf0700456Pharma Surgeen2026-07-30T07:32:08.000ZA Maternal GBS Vaccine Just Cleared Phase 1/2. Here’s What the Trial Design Tells Us About the Regulatory Gauntlet Ahead.https://www.pharmaradar360.com/article/guidance-london-region-i-mhra-regulatory-sandbox-call-for-expressions-of-interes-468724226ce1adadPharma Surgeen2026-07-30T07:28:00.000ZGuidance: London Region I MHRA Regulatory Sandbox: call for expressions of interesthttps://www.pharmaradar360.com/article/workwell-1415ead5314a3eeaPharma Surgeen2026-07-30T07:24:00.000ZWorkWellhttps://www.pharmaradar360.com/article/benzodiazepines-en-aanverwante-geneesmiddelen-herhaling-van-de-aanbevelingen-voo-2f8e2bd794554a15Pharma Surgeen2026-07-30T07:22:52.000ZBenzodiazepines en aanverwante geneesmiddelen: herhaling van de aanbevelingen voor een rationeel gebruikhttps://www.pharmaradar360.com/article/does-biomarin-bmrn-expanding-into-renu-syndrome-refine-its-rare-disease-pipeline-bc1c8a4f8f049d63Pharma Surgeen2026-07-30T07:15:07.000ZDoes BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy?https://www.pharmaradar360.com/article/takeda-pharmaceutical-4502-earnings-strong-1q-beats-estimates-with-net-income-at-9591ff56eb0a2577Pharma Surgeen2026-07-30T06:50:49.000ZTakeda Pharmaceutical (4502) Earnings: Strong 1Q Beats Estimates with Net Income at 113.2 Billion Yenhttps://www.pharmaradar360.com/article/double-shifts-work-pressure-maharashtra-food-safety-body-head-faces-staff-shorta-d11ce877ca9cd2b8Pharma Surgeen2026-07-30T06:47:06.000Z'Double Shifts, Work Pressure': Maharashtra Food Safety Body Head Faces 'Staff Shortage' Complainthttps://www.pharmaradar360.com/article/viking-therapeutics-advances-vk2735-oral-program-into-phase-3-trials-aa8acd481d3712d6Pharma Surgeen2026-07-30T06:36:50.000ZViking Therapeutics Advances VK2735 Oral Program Into Phase 3 Trialshttps://www.pharmaradar360.com/article/beijing-hanmi-profit-nearly-vanishes-amid-receivables-concerns-885bfdde94dad1f2Pharma Surgeen2026-07-30T06:23:14.000ZBeijing Hanmi Profit Nearly Vanishes Amid Receivables Concernshttps://www.pharmaradar360.com/article/150426-lolota-professional-nails-uv-uv-led-gel-polish-46-eb03349d5e4bea4aPharma Surgeen2026-07-30T06:19:52.000ZΑνάκληση της παρτίδας 150426 του Καλλυντικού προϊόντος Lolota Professional nails UV& UV LED GEL POLISH 46https://www.pharmaradar360.com/article/gsk-strikes-ai-deal-with-uk-biotech-to-boost-early-pipeline-8d7b821518d58eb4Pharma Surgeen2026-07-30T06:00:00.000ZGSK Strikes AI Deal With UK Biotech to Boost Early Pipelinehttps://www.pharmaradar360.com/article/fda-ban-on-sale-of-junk-food-within-50-meters-of-schools-major-decision-by-the-f-95d8b5a51679962aPharma Surgeen2026-07-30T05:50:04.000ZFDA: Ban on Sale of Junk Food within 50 Meters of Schools; Major Decision by the Food and Drug Administrationhttps://www.pharmaradar360.com/article/the-top-5-analyst-questions-from-thermo-fisher-s-q2-earnings-call-b079b99314c28b34Pharma Surgeen2026-07-30T05:43:00.000ZThe Top 5 Analyst Questions From Thermo Fisher’s Q2 Earnings Callhttps://www.pharmaradar360.com/article/seize-the-golden-window-for-biotech-ipos-attovia-aims-to-raise-up-to-212-5-milli-8ac8d1fbd092cdd9Pharma Surgeen2026-07-30T05:37:58.000ZSeize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debuthttps://www.pharmaradar360.com/article/excellent-growth-and-progress-in-h1-2026-ef864d88f3d12173Pharma Surgeen2026-07-30T05:16:12.000ZExcellent growth and progress in H1 2026https://www.pharmaradar360.com/article/bombay-high-court-seeks-inspection-details-of-government-canteens-amid-fda-enfor-5b63108acf7cf3fdPharma Surgeen2026-07-30T05:15:56.000ZBombay High Court Seeks Inspection Details of Government Canteens Amid FDA Enforcement Drivehttps://www.pharmaradar360.com/article/cspc-hunan-jingfeng-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-000908-42176037344361caPharma Surgeen2026-07-30T05:10:48.000ZCSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A Revenue Breakdown – SZSE:000908https://www.pharmaradar360.com/article/conserving-tropical-forests-could-preserve-billions-of-dollars-in-pharmaceutical-623f935b271ac85cPharma Surgeen2026-07-30T05:02:55.000ZConserving tropical forests could preserve billions of dollars in pharmaceutical value from undiscovered drugshttps://www.pharmaradar360.com/article/bombay-hc-asks-maharashtra-govt-to-give-details-of-fda-inspections-at-state-run-00d8a60d95ac026fPharma Surgeen2026-07-30T05:01:04.000ZBombay HC asks Maharashtra govt. to give details of FDA inspections at State-run canteens, eating placeshttps://www.pharmaradar360.com/article/daewoong-s-botulinum-toxin-nabota-enters-kuwait-796978f06b04efc8Pharma Surgeen2026-07-30T04:50:15.000ZDaewoong's botulinum toxin Nabota enters Kuwaithttps://www.pharmaradar360.com/article/the-lancet-bloodstream-delivered-cell-therapy-slows-muscle-decline-in-1423241d925dedd0Pharma Surgeen2026-07-30T04:01:40.000ZThe Lancet: Bloodstream-delivered cell therapy slows muscle decline inhttps://www.pharmaradar360.com/article/the-results-suggest-the-potential-usefulness-of-s-equol-in-women-with-severe-sym-54ff3192e96597eaPharma Surgeen2026-07-30T04:00:00.000ZThe Results Suggest the Potential Usefulness of S-Equol in Women with Severe Symptoms of PMS and PMDD New Findings Contribute to Advancing Support for Women's Healthhttps://www.pharmaradar360.com/article/brve-ipo-news-cardiovascular-diseases-biotech-braveheart-bio-sets-terms-for-300-6bcecb78a9df1f6fPharma Surgeen2026-07-30T04:00:00.000ZBRVE IPO News - Cardiovascular diseases biotech Braveheart Bio sets terms for $300 million IPOhttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments-4f8a318690bf03caPharma Surgeen2026-07-30T04:00:00.000ZFDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatmentshttps://www.pharmaradar360.com/article/convenience-kit-correction-argon-medical-issues-correction-for-convenience-kits-10d22291a8e48e53Pharma Surgeen2026-07-30T04:00:00.000ZConvenience Kit Correction: Argon Medical Issues Correction for Convenience Kits Containing Spectra Medical Device Lidocaine Ampuleshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-honz-pharmaceutical-co-ltd-class-a-szse-30-8e1b3cdef3ff6611Pharma Surgeen2026-07-30T03:36:08.000ZEnterprise value to EBITDA forward of Honz Pharmaceutical Co., Ltd. Class A – SZSE:300086https://www.pharmaradar360.com/article/families-gather-at-state-capitol-to-mark-prescribed-harm-awareness-day-70bfdd52cd81d003Pharma Surgeen2026-07-30T03:25:00.000ZFamilies gather at state capitol to mark Prescribed Harm Awareness Dayhttps://www.pharmaradar360.com/article/asca2026-last-chance-to-get-early-bird-discount-4eba3a77cedaa463Pharma Surgeen2026-07-30T02:43:53.000ZASCA2026: Last Chance to Get Early Bird Discounthttps://www.pharmaradar360.com/article/12-funding-rounds-that-show-where-apac-biotech-capital-is-going-ca8fd3e7804f69f6Pharma Surgeen2026-07-30T02:26:32.000Z12 Funding Rounds That Show Where APAC Biotech Capital Is Goinghttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-expands-patent-portfolio-to-support-next-generation-c-dc049ad67e7e53e2Pharma Surgeen2026-07-30T01:55:47.000ZVERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platformshttps://www.pharmaradar360.com/article/dimerix-asx-dxb-builds-pipeline-momentum-with-phase-3-progress-and-new-commercia-c362f2bb116cbf0ePharma Surgeen2026-07-30T01:53:00.000ZDimerix (ASX:DXB) Builds Pipeline Momentum With Phase 3 Progress and New Commercial Partnershiphttps://www.pharmaradar360.com/article/alterity-therapeutics-asx-ath-gains-ground-as-fda-clears-pathway-toward-ath434-p-57be5a1ea08d056dPharma Surgeen2026-07-30T01:34:00.000ZAlterity Therapeutics (ASX:ATH) Gains Ground as FDA Clears Pathway Toward ATH434 Phase 3 Trialhttps://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-e3c394a5c6571806Pharma Surgeen2026-07-30T01:10:01.000ZPrecision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zoneshttps://www.pharmaradar360.com/article/actinogen-medical-keeps-pivotal-alzheimer-s-trial-on-track-for-november-readout-306243b24d872049Pharma Surgeen2026-07-30T01:07:56.000ZActinogen Medical keeps pivotal Alzheimer’s trial on track for November readouthttps://www.pharmaradar360.com/article/k-cab-eyes-fda-approval-after-dominating-home-market-expanding-abroad-673b1dadcb993ed5Pharma Surgeen2026-07-30T00:40:38.000ZK-CAB eyes FDA approval after dominating home market, expanding abroadhttps://www.pharmaradar360.com/article/krystal-biotech-krys-is-up-7-9-after-s-p-400-move-and-new-kb801-patent-filing-up-245c39255f31ed89Pharma Surgeen2026-07-30T00:15:00.000ZKrystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Updatehttps://www.pharmaradar360.com/article/fifarma-se-une-a-alianca-para-a-eliminacao-do-hiv-nas-americas-f454cfc33f89a84bPharma Surgeen2026-07-30T00:03:36.000ZFIFARMA se une à Aliança para a Eliminação do HIV nas Américashttps://www.pharmaradar360.com/article/regeneron-filed-form-10-q-e146c874447d680ePharma Surgeen2026-07-30T00:00:00.000ZRegeneron filed Form 10-Qhttps://www.pharmaradar360.com/article/regeneron-filed-form-8-k-ed6150eae8b55ce7Pharma Surgeen2026-07-30T00:00:00.000ZRegeneron filed Form 8-Khttps://www.pharmaradar360.com/article/bristol-myers-squibb-filed-form-10-q-e7c46151ac5b7a43Pharma Surgeen2026-07-30T00:00:00.000ZBristol Myers Squibb filed Form 10-Qhttps://www.pharmaradar360.com/article/bristol-myers-squibb-filed-form-8-k-5fb0abd30782d61dPharma Surgeen2026-07-30T00:00:00.000ZBristol Myers Squibb filed Form 8-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-d0b4ae79765c07fcPharma Surgeen2026-07-30T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-5d761ce50a94660dPharma Surgeen2026-07-30T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-e834069d41e93075Pharma Surgeen2026-07-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-9c09f11a0c5a5b65Pharma Surgeen2026-07-30T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-ef6875e08aabf779Pharma Surgeen2026-07-30T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9d1cd0d591ebe880Pharma Surgeen2026-07-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-8fda7b74cca97186Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-7595edfcb4bacf41Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-493e85cd0214acffPharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-291f29425ffdc0a8Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-acf055487841539cPharma Surgeen2026-07-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-f1898a816e218040Pharma Surgeen2026-07-30T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-1e5e8b3a112a3cb7Pharma Surgeen2026-07-30T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-9c9b8655c5caaa26Pharma Surgeen2026-07-30T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-77bbdeb11256516cPharma Surgeen2026-07-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-updates-to-the-master-list-of-items-potentially-subject-to-face-fa9cad9b91ad1b04Pharma Surgeen2026-07-30T00:00:00.000ZMedicare Program; Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Priorhttps://www.pharmaradar360.com/article/butylated-hydroxytoluene-bht-request-for-information-reopening-of-comment-period-252ead25512fc469Pharma Surgeen2026-07-30T00:00:00.000ZButylated Hydroxytoluene (BHT); Request for Information; Reopening of Comment Periodhttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-meeting-dfa90160a9ccc0aaPharma Surgeen2026-07-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Meetinghttps://www.pharmaradar360.com/article/office-of-the-secretary-amended-notice-of-meeting-b09adaf1582e0e15Pharma Surgeen2026-07-30T00:00:00.000ZOffice of the Secretary; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-6c749fa6d7f34eb8Pharma Surgeen2026-07-30T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Health Center Program Forms-OMB No. 0915-0285-Revisionhttps://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-single-source-grants-multiple-recipients-for-7b36125533c55e88Pharma Surgeen2026-07-30T00:00:00.000ZAnnouncement of the Intent To Award Single-Source Grants (Multiple Recipients) for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ianhttps://www.pharmaradar360.com/article/administrative-costs-for-children-in-title-iv-e-foster-care-151a2ee941d51272Pharma Surgeen2026-07-30T00:00:00.000ZAdministrative Costs for Children in Title IV-E Foster Carehttps://www.pharmaradar360.com/article/biosimilar-user-fee-rates-for-fiscal-year-2027-d8c1235e33c86495Pharma Surgeen2026-07-30T00:00:00.000ZBiosimilar User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-voluntary-qualified-importer-program-user-fee-rate-8ff28f383bbbdec4Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027https://www.pharmaradar360.com/article/over-the-counter-monograph-drug-user-fee-rates-for-fiscal-year-2027-7661e36b3b13b2e9Pharma Surgeen2026-07-30T00:00:00.000ZOver-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/generic-drug-user-fee-rates-for-fiscal-year-2027-c7e23551b9f647b2Pharma Surgeen2026-07-30T00:00:00.000ZGeneric Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/outsourcing-facility-fee-rates-for-fiscal-year-2027-593ae882eb5aeff2Pharma Surgeen2026-07-30T00:00:00.000ZOutsourcing Facility Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/animal-generic-drug-user-fee-program-rates-and-payment-procedures-for-fiscal-yea-a84d8bd7895c195fPharma Surgeen2026-07-30T00:00:00.000ZAnimal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027https://www.pharmaradar360.com/article/animal-drug-user-fee-rates-and-payment-procedures-for-fiscal-year-2027-be13b839dffa2784Pharma Surgeen2026-07-30T00:00:00.000ZAnimal Drug User Fee Rates and Payment Procedures for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-third-party-certification-program-user-fee-rate-fo-1ecca3a8b6afb940Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-domestic-and-foreign-facility-reinspection-recall-a8c8ae52a78a26e1Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/medical-device-user-fee-rates-for-fiscal-year-2027-6e2aa92b0b39d0b0Pharma Surgeen2026-07-30T00:00:00.000ZMedical Device User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/prescription-drug-user-fee-rates-for-fiscal-year-2027-7b8444f17d25a519Pharma Surgeen2026-07-30T00:00:00.000ZPrescription Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-93425e484c351057Pharma Surgeen2026-07-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-amended-notice-of-meeting-8a7f1e0f87a7d848Pharma Surgeen2026-07-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/joan-rubinger-n-p-decision-and-order-f33d5dcdbae95a70Pharma Surgeen2026-07-30T00:00:00.000ZJoan Rubinger, N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-96f5b4c5135c534fPharma Surgeen2026-07-30T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/national-center-for-health-statistics-meeting-of-the-icd-10-coordination-and-mai-274c9e55cbd81bdcPharma Surgeen2026-07-30T00:00:00.000ZNational Center for Health Statistics, Meeting of the ICD-10 Coordination and Maintenance Committeehttps://www.pharmaradar360.com/article/drug-label-update-cefpodoxime-proxetil-8858f869e5ff7349Pharma Surgeen2026-07-30T00:00:00.000ZDrug label update: Cefpodoxime Proxetilhttps://www.pharmaradar360.com/article/siemens-healthineers-cleveland-clinic-launch-10-year-strategic-alliance-to-enhan-a49cff4572f9ae0aPharma Surgeen2026-07-30T00:00:00.000ZSiemens Healthineers, Cleveland Clinic Launch 10-year Strategic Alliance to Enhance Care Through Advanced Imaginghttps://www.pharmaradar360.com/article/ember-lifesciences-and-alfresa-corporation-enter-into-capital-and-business-allia-da7c1bb39c6830fePharma Surgeen2026-07-30T00:00:00.000ZEmber LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japanhttps://www.pharmaradar360.com/article/evaluating-the-citation-accuracy-of-chatgpt-5-using-the-american-academy-of-orth-1acacea4085cc91aPharma Surgeen2026-07-30T00:00:00.000ZEvaluating the Citation Accuracy of ChatGPT-5 Using the American Academy of Orthopaedic Surgeons Clinical Practice Guidelineshttps://www.pharmaradar360.com/article/pediatric-acute-leukemias-epidemiological-clinical-features-and-diagnostic-contr-7a74ab6a3d40583ePharma Surgeen2026-07-30T00:00:00.000ZPediatric Acute Leukemias: Epidemiological, Clinical Features, and Diagnostic Contribution of Flow Cytometry in a Resource-Limited Settinghttps://www.pharmaradar360.com/article/clinical-efficacy-and-patient-adherence-hurdles-of-remote-patient-monitoring-rpm-21f9d849f043d4d0Pharma Surgeen2026-07-30T00:00:00.000ZClinical Efficacy and Patient Adherence Hurdles of Remote Patient Monitoring (RPM) Frameworks in Managing Hypertension and Type 2 Diabetes: A Scoping Reviewhttps://www.pharmaradar360.com/article/review-of-computer-aided-detection-cad-software-for-tuberculosis-on-chest-x-rays-147c3abbbf57e00aPharma Surgeen2026-07-30T00:00:00.000ZReview of Computer-Aided Detection (CAD) Software for Tuberculosis on Chest X-Rays : A Systematic Review of Randomized Controlled Trial and Primary Studieshttps://www.pharmaradar360.com/article/impacto-de-la-formacion-practica-en-pediatria-en-la-aplicacion-del-proceso-de-at-9076d2cdf64db7b1Pharma Surgeen2026-07-30T00:00:00.000ZImpacto de la formación práctica en pediatría en la aplicación del Proceso de Atención de Enfermería por estudiantes de enfermeríahttps://www.pharmaradar360.com/article/grant-writing-coaching-groups-a-randomized-trial-to-discern-the-influences-of-co-ebfef0e41cde0e21Pharma Surgeen2026-07-30T00:00:00.000ZGrant writing coaching groups: A randomized trial to discern the influences of coaching duration and engagement of scientific mentors on participants’ proposal submission and success rateshttps://www.pharmaradar360.com/article/3-clinical-grade-skincare-creams-you-really-shouldn-t-buy-online-d34a5f1696979893Pharma Surgeen2026-07-30T00:00:00.000Z3 clinical-grade skincare creams you really shouldn’t buy onlinehttps://www.pharmaradar360.com/article/intravenous-insulin-protocol-reduces-time-to-target-glucose-in-critically-ill-tr-36fb4870b8cef011Pharma Surgeen2026-07-30T00:00:00.000ZIntravenous insulin protocol reduces time to? target glucose in critically ill trauma and burn? patientshttps://www.pharmaradar360.com/article/case-report-necrotizing-enterocolitis-with-gastric-perforation-in-a-24-day-old-p-094bec4bb63b083aPharma Surgeen2026-07-30T00:00:00.000ZCase Report: Necrotizing Enterocolitis with Gastric Perforation in a 24-day old preterm neonatehttps://www.pharmaradar360.com/article/efficacy-of-gabapentin-versus-trospium-chloride-for-prevention-of-catheter-relat-a5f07981fefd74ddPharma Surgeen2026-07-30T00:00:00.000ZEfficacy of gabapentin versus trospium chloride for prevention of catheter-related bladder discomfort inside the surgical intensive care unit: A prospective, randomised, controlled clinical studyhttps://www.pharmaradar360.com/article/evaluation-of-the-relationship-between-mini-nutritional-assessment-short-form-an-4ca7fca82ff2cee5Pharma Surgeen2026-07-30T00:00:00.000ZEvaluation of the relationship between mini nutritional assessment-short form and prognostic nutritional index in individuals aged 80 years and olderhttps://www.pharmaradar360.com/article/chalcones-as-versatile-scaffolds-in-drug-design-synthesis-structure-activity-rel-85688b23142524ccPharma Surgeen2026-07-30T00:00:00.000ZChalcones as versatile scaffolds in drug design: synthesis, structure–activity relationship (sar), and anticancer potentialhttps://www.pharmaradar360.com/article/beyond-clinical-care-the-influence-of-psychosocial-support-trust-and-service-qua-7f131739f3dbc758Pharma Surgeen2026-07-30T00:00:00.000ZBeyond Clinical Care: The Influence of Psychosocial Support, Trust, and Service Quality on Patient Satisfactionhttps://www.pharmaradar360.com/article/anatomy-driven-dysphagia-after-technically-successful-peroral-endoscopic-myotomy-14e82054035cde4dPharma Surgeen2026-07-30T00:00:00.000ZAnatomy-driven dysphagia after technically successful peroral endoscopic myotomy in sigmoid-shape achalasia: short-term palliation with temporary fully covered self-expanding metal stentshttps://www.pharmaradar360.com/article/percutaneous-endoscopic-gastrostomy-with-jejunal-extension-versus-direct-percuta-c17fc4a40d85a3b4Pharma Surgeen2026-07-30T00:00:00.000ZPercutaneous endoscopic gastrostomy with jejunal extension versus direct percutaneous endoscopic jejunostomy: patient-related outcomes and complicationshttps://www.pharmaradar360.com/article/treatment-procedures-for-intractable-gastroesophageal-reflux-disease-after-peror-f84649beef53cf84Pharma Surgeen2026-07-30T00:00:00.000ZTreatment procedures for intractable gastroesophageal reflux disease after peroral endoscopic myotomy for achalasia: a retrospective study in South Koreahttps://www.pharmaradar360.com/article/effect-of-dose-tapering-policy-on-the-prescription-of-advanced-therapy-for-rheum-51bb3de9e5c0e173Pharma Surgeen2026-07-30T00:00:00.000ZEffect of dose tapering policy on the prescription of advanced therapy for rheumatoid arthritis: a retrospective analysis of clinical and cost outcomes in Taiwanhttps://www.pharmaradar360.com/article/digital-leadership-and-individual-employee-performance-in-a-quality-oriented-org-6685b0b11a373b5ePharma Surgeen2026-07-30T00:00:00.000ZDIGITAL LEADERSHIP AND INDIVIDUAL EMPLOYEE PERFORMANCE IN A QUALITY-ORIENTED ORGANIZATIONAL CLIMATE: EVIDENCE FROM THE TURKISH PHARMACEUTICAL INDUSTRYhttps://www.pharmaradar360.com/article/clinical-outcomes-of-ultrasound-guided-pulsed-radiofrequency-and-radiofrequency-ef2820629344d38aPharma Surgeen2026-07-30T00:00:00.000ZClinical Outcomes of Ultrasound-Guided Pulsed Radiofrequency and Radiofrequency Ablation of the Genicular Nerves in Knee Osteoarthritishttps://www.pharmaradar360.com/article/clinical-and-diagnostic-features-of-pediatric-multiple-sclerosis-325a926f3cf9b3c1Pharma Surgeen2026-07-30T00:00:00.000ZCLINICAL AND DIAGNOSTIC FEATURES OF PEDIATRIC MULTIPLE SCLEROSIShttps://www.pharmaradar360.com/article/osint-d416afec4f53cf3cPharma Surgeen2026-07-30T00:00:00.000ZМЕТОДИКА ІНТЕГРАЦІЇ ДАНИХ OSINT У СИСТЕМУ КРИМІНАЛЬНОГО ДОКАЗУВАННЯ НА СТАДІЇ ДОСУДОВОГО РОЗСЛІДУВАННЯhttps://www.pharmaradar360.com/article/confocal-laser-endomicroscopy-with-duodenal-food-challenge-does-not-predict-trig-556e6c78a5935758Pharma Surgeen2026-07-30T00:00:00.000ZConfocal Laser Endomicroscopy With Duodenal Food Challenge Does Not Predict Triggering Food Items in Eosinophilic Esophagitis: Results From a Pilot Trialhttps://www.pharmaradar360.com/article/impact-of-synthesis-temperature-on-the-drug-loading-capacity-of-linde-type-a-zeo-9569f322e8f3c525Pharma Surgeen2026-07-30T00:00:00.000ZImpact of Synthesis Temperature on the Drug Loading Capacity of Linde Type A Zeolitehttps://www.pharmaradar360.com/article/comparative-analysis-of-performance-evaluation-for-stroke-risk-prediction-based-117981bedf30cf25Pharma Surgeen2026-07-30T00:00:00.000ZCOMPARATIVE ANALYSIS OF PERFORMANCE EVALUATION FOR STROKE RISK PREDICTION BASED ON CLINICAL DATAhttps://www.pharmaradar360.com/article/severe-hbv-associated-hepatitis-in-infants-from-the-same-family-two-clinical-cas-44c1a35479b8491aPharma Surgeen2026-07-30T00:00:00.000ZSevere HBV-Associated Hepatitis in Infants from the Same Family: Two Clinical Cases with Different Outcomeshttps://www.pharmaradar360.com/article/effect-of-tomato-consumption-on-liver-steatosis-in-masld-a-randomized-controlled-12da74e043306ddbPharma Surgeen2026-07-30T00:00:00.000ZEffect of Tomato Consumption on Liver Steatosis in MASLD: A Randomized Controlled Trial (POMOSANO Study)https://www.pharmaradar360.com/article/nutrition-behaviour-during-pregnancy-eating-twice-as-healthy-a-secondary-analysi-6438d6981ace7338Pharma Surgeen2026-07-30T00:00:00.000ZNutrition Behaviour During Pregnancy: Eating Twice as Healthy? A Secondary Analysis of the Nutrition Component of the NELIP Randomized Controlled Trialhttps://www.pharmaradar360.com/article/explainable-retrospective-sepsis-classification-based-on-elixhauser-comorbidity-93b4f8942ed209fcPharma Surgeen2026-07-30T00:00:00.000ZExplainable Retrospective Sepsis Classification Based on Elixhauser Comorbidity Groups Using Machine and Deep Learning on MIMIC-IVhttps://www.pharmaradar360.com/article/the-effects-of-breast-cancer-surgery-on-thoracic-kyphosis-and-the-correlation-be-f874dfed90884965Pharma Surgeen2026-07-30T00:00:00.000ZThe Effects of Breast Cancer Surgery on Thoracic Kyphosis and the Correlation Between Supine CT and Standing X-Rays: A Single-Center Retrospective Studyhttps://www.pharmaradar360.com/article/actual-hydrated-volume-of-acellular-dermal-matrix-in-prepectoral-breast-reconstr-f8f10544d5eb7f0cPharma Surgeen2026-07-30T00:00:00.000ZActual Hydrated Volume of Acellular Dermal Matrix in Prepectoral Breast Reconstructionhttps://www.pharmaradar360.com/article/restoring-ventricular-geometry-left-ventricular-reconstruction-in-a-patient-with-6ce210d563292592Pharma Surgeen2026-07-30T00:00:00.000ZRestoring Ventricular Geometry: Left Ventricular Reconstruction in a Patient with a Giant Left Ventricular Aneurysm and End-Stage Heart Failurehttps://www.pharmaradar360.com/article/assessment-of-care-transition-of-post-covid-19-patients-in-brazil-association-wi-d39044eb90390bf9Pharma Surgeen2026-07-30T00:00:00.000ZAssessment of Care Transition of Post-COVID-19 Patients in Brazil: Association with Sociodemographic and Clinical Characteristicshttps://www.pharmaradar360.com/article/pathogen-characteristics-and-pre-index-clinical-factors-associated-with-multidru-2c034bddb3803ef8Pharma Surgeen2026-07-30T00:00:00.000ZPathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patientshttps://www.pharmaradar360.com/article/from-benchmark-accuracy-to-pharmacological-credibility-why-mechanistic-explainab-c980b8abe0644634Pharma Surgeen2026-07-30T00:00:00.000ZFrom benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposinghttps://www.pharmaradar360.com/article/integrative-conservative-rehabilitation-for-adolescent-idiopathic-scoliosis-a-ra-dd53d70d3c01b57bPharma Surgeen2026-07-30T00:00:00.000ZIntegrative conservative rehabilitation for adolescent idiopathic scoliosis: a randomized controlled trial of traditional Chinese manual therapy combined with Schroth traininghttps://www.pharmaradar360.com/article/retrospective-analysis-of-the-clinical-value-of-targeted-nursing-using-a-game-ba-9e26695ea4471807Pharma Surgeen2026-07-30T00:00:00.000ZRetrospective analysis of the clinical value of targeted nursing using a game-based model in children undergoing auricular reconstruction for congenital microtiahttps://www.pharmaradar360.com/article/effects-of-curcuma-longa-extract-on-cognitive-function-in-healthy-participants-w-8df4307597a96aeaPharma Surgeen2026-07-30T00:00:00.000ZEffects of Curcuma longa extract on cognitive function in healthy participants with subtle cognitive weaknesses within the normal range: a randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/a-digital-platform-based-stratified-intervention-for-preventing-disability-risk-ab64c10665e10b12Pharma Surgeen2026-07-30T00:00:00.000ZA digital platform-based stratified intervention for preventing disability risk in community-dwelling older adults: study protocol for a randomized multicenter trialhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-machine-learning-models-for-gouty-arthrit-ad6dbdba1b09aa69Pharma Surgeen2026-07-30T00:00:00.000ZDevelopment and internal validation of machine learning models for gouty arthritis classification using routine clinical variables: a retrospective studyhttps://www.pharmaradar360.com/article/clinical-study-of-remimazolam-combined-with-ultrasound-guided-superior-laryngeal-05d06729d83c8122Pharma Surgeen2026-07-30T00:00:00.000ZClinical study of remimazolam combined with ultrasound-guided superior laryngeal nerve block in elderly patients with coronary heart disease undergoing bronchoscopyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-the-traditional-chinese-medicine-formulation-bl-1-for-the-0047ca52d4fbc1ccPharma Surgeen2026-07-30T00:00:00.000ZEfficacy and safety of the traditional Chinese medicine formulation BL-1 for the treatment of low anterior resection syndrome: study protocol for a double-blind, randomized, placebo-controlled trialhttps://www.pharmaradar360.com/article/hepatic-tubercular-abscess-due-to-paradoxical-tb-iris-during-anti-tubercular-the-cd2360dda4da89a2Pharma Surgeen2026-07-30T00:00:00.000ZHepatic tubercular abscess due to paradoxical TB-IRIS during anti-tubercular therapy with concurrent drug-induced liver injury: a case reporthttps://www.pharmaradar360.com/article/effectiveness-of-phytoestrogen-nutrition-education-on-knowledge-and-practice-of-7eb82126c3d16afePharma Surgeen2026-07-30T00:00:00.000ZEffectiveness of Phytoestrogen Nutrition Education on Knowledge and Practice of Phytoestrogen Diet Among Perimenopausal Women at Selected Institutions of Ramaiah University of Applied Sciences, Bengaluruhttps://www.pharmaradar360.com/article/pediatric-epidermolysis-bullosa-amp-8211-psychosocial-impact-and-the-importance-3c8121521c4dc288Pharma Surgeen2026-07-30T00:00:00.000ZPediatric epidermolysis bullosa – psychosocial impact and the importance of palliative care based on 5 clinical caseshttps://www.pharmaradar360.com/article/primary-erythromelalgia-a-clinical-diagnosis-f45fea7ba3e5c702Pharma Surgeen2026-07-30T00:00:00.000ZPrimary erythromelalgia: a clinical diagnosishttps://www.pharmaradar360.com/article/serial-clinical-observation-in-early-neonatal-sepsis-insights-from-a-national-po-55922526010f7b68Pharma Surgeen2026-07-30T00:00:00.000ZSerial clinical observation in early neonatal sepsis: insights from a national portuguese surveyhttps://www.pharmaradar360.com/article/f144db071f3c5f3dPharma Surgeen2026-07-30T00:00:00.000ZКоличественная оценка результатов иммуногистохимического исследования: современные подходы и ограничения методаhttps://www.pharmaradar360.com/article/12-38be10c07e11f794Pharma Surgeen2026-07-30T00:00:00.000ZСистемный анализ трёхэтапной схемы сегментационного предобучения для выявления признаков инфаркта миокарда по электрокардиограмме в 12 отведенияхhttps://www.pharmaradar360.com/article/lt-i-gt-chondrus-armatus-lt-i-gt-e9638e0dda937c1ePharma Surgeen2026-07-30T00:00:00.000ZАнтиоксидантная и радикал-связывающая активность нативных и деполимеризованных κ- и λ-каррагинанов красной водоросли <i>Chondrus armatus</i>https://www.pharmaradar360.com/article/the-effectiveness-of-acceptance-and-commitment-therapy-on-marital-functioning-em-826b930cb29f7b8dPharma Surgeen2026-07-30T00:00:00.000ZThe Effectiveness of Acceptance and Commitment Therapy on Marital Functioning, Emotion Regulation, and Secondary Traumatic Stress Symptoms in Wives of Soldiers with Post-Traumatic Stress Disorder: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/long-term-effectiveness-of-combination-antiretroviral-therapy-and-drug-resistanc-c855048c27aa50a3Pharma Surgeen2026-07-30T00:00:00.000ZLong-Term Effectiveness of combination Antiretroviral Therapy and Drug Resistance Patterns Among People living with HIV in Benghazi, Libya: Retrospective cohort Study (2009 – 2014)https://www.pharmaradar360.com/article/clinical-outcomes-following-implementation-of-an-early-enteral-nutrition-initiat-ae017edd08f8f590Pharma Surgeen2026-07-30T00:00:00.000ZClinical outcomes following implementation of an early enteral nutrition initiation and monitoring approach in critically ill ventilated patients: a historical-control observational studyhttps://www.pharmaradar360.com/article/aggressive-pituitary-neuroendocrine-tumours-display-a-distinct-immune-microenvir-911b141abe6b763bPharma Surgeen2026-07-30T00:00:00.000ZAggressive pituitary neuroendocrine tumours display a distinct immune microenvironmenthttps://www.pharmaradar360.com/article/the-effect-of-an-indirect-anchorage-reinforcement-device-on-maxillary-anterior-i-3bb17bacddb8650bPharma Surgeen2026-07-30T00:00:00.000ZThe effect of an indirect anchorage reinforcement device on maxillary anterior intrusion with clear aligners: a three-dimensional finite element analysis and exploratory clinical validationhttps://www.pharmaradar360.com/article/organelle-specific-mechanisms-and-ai-guided-stratification-in-gut-renal-vascular-0ce5ca2d5c618abfPharma Surgeen2026-07-30T00:00:00.000ZOrganelle-specific mechanisms and AI-guided stratification in gut-renal-vascular axis modulationhttps://www.pharmaradar360.com/article/eight-weeks-of-focal-muscle-vibration-shows-improvements-in-muscle-co-ordination-6fdec247a7d14e99Pharma Surgeen2026-07-30T00:00:00.000ZEight weeks of focal muscle vibration shows improvements in muscle co-ordination and co-contraction in cerebral palsy children: a randomized control trialhttps://www.pharmaradar360.com/article/trial-reported-arthralgia-of-androgen-deprivation-therapy-plus-androgen-receptor-990f9173aab8c8e7Pharma Surgeen2026-07-30T00:00:00.000ZTrial-reported arthralgia of androgen deprivation therapy plus androgen receptor signaling inhibitors in prostate cancer: evidence from phase III randomized trialshttps://www.pharmaradar360.com/article/clinical-validation-of-a-novel-framework-for-dyspnoea-investigation-with-cpet-in-40af5ed1d3ef8125Pharma Surgeen2026-07-30T00:00:00.000ZClinical Validation of a Novel Framework for Dyspnoea Investigation with CPET in COPDhttps://www.pharmaradar360.com/article/artificially-intelligent-simulated-patients-in-undergraduate-surgical-teaching-a-e09bb84f55731098Pharma Surgeen2026-07-30T00:00:00.000ZArtificially Intelligent Simulated Patients in Undergraduate Surgical Teaching: A Single Blinded Randomized Controlled Studyhttps://www.pharmaradar360.com/article/peer-recovery-care-planning-while-awaiting-alcohol-and-other-drug-treatment-1590d073a3a070b3Pharma Surgeen2026-07-30T00:00:00.000ZPeer Recovery Care Planning While Awaiting Alcohol and Other Drug Treatmenthttps://www.pharmaradar360.com/article/long-term-outcomes-of-gonadotropin-releasing-hormone-analogue-therapy-in-central-9d4542887794fc37Pharma Surgeen2026-07-30T00:00:00.000ZLong‐Term Outcomes of Gonadotropin‐Releasing Hormone Analogue Therapy in Central Precocious Puberty: A Comparative Analysis of Obese and Normal‐Weight Girlshttps://www.pharmaradar360.com/article/maternal-neonatal-metabolic-continuity-and-early-postnatal-hpg-axis-activity-in-da500d3342b9ff27Pharma Surgeen2026-07-30T00:00:00.000ZMaternal–Neonatal Metabolic Continuity and Early Postnatal HPG Axis Activity in Healthy Term Neonateshttps://www.pharmaradar360.com/article/correction-to-assessment-of-an-infectious-disease-econsult-service-at-a-large-mi-14d670cc846a6bedPharma Surgeen2026-07-30T00:00:00.000ZCorrection to: Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare Systemhttps://www.pharmaradar360.com/article/efficacy-of-targeted-neuromodulation-treatments-a-clinical-report-90f1b12c9a93676fPharma Surgeen2026-07-30T00:00:00.000ZEfficacy of targeted neuromodulation treatments: a clinical reporthttps://www.pharmaradar360.com/article/intraocular-retinoblastoma-features-and-treatment-outcomes-according-to-patient-f415634a52e73d73Pharma Surgeen2026-07-30T00:00:00.000ZIntraocular retinoblastoma features and treatment outcomes according to patient age at initial presentationhttps://www.pharmaradar360.com/article/automated-readings-of-imaging-reports-by-natural-language-processing-nlp-supplem-fbc347139701a483Pharma Surgeen2026-07-30T00:00:00.000ZAutomated readings of imaging reports by natural language processing (NLP) supplemented by clinical data predict disease course in children and adults with Crohn’s disease: report from the epi-IIRNhttps://www.pharmaradar360.com/article/clinical-utility-of-ubiliquins-in-breast-cancer-pubmed-17c08e8cfd159a29Pharma Surgeen2026-07-30T00:00:00.000ZClinical utility of ubiliquins in breast cancer (PubMed).https://www.pharmaradar360.com/article/harnessing-liver-heart-crosstalk-via-extracellular-vesicle-mediated-hepatic-deli-0337ecfca1290f79Pharma Surgeen2026-07-30T00:00:00.000ZHarnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repairhttps://www.pharmaradar360.com/article/safety-feasibility-and-preliminary-clinical-outcomes-of-psilocybin-assisted-ther-2f46c63a83c2928aPharma Surgeen2026-07-30T00:00:00.000ZSafety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialhttps://www.pharmaradar360.com/article/clinical-toxicity-of-adcs-and-ici-adc-combinations-mechanisms-patterns-and-manag-20b0c8425a12116fPharma Surgeen2026-07-30T00:00:00.000ZClinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and managementhttps://www.pharmaradar360.com/article/trial-by-fire-uncertainty-and-adaptive-management-in-forest-ecology-c60abc33dfcea279Pharma Surgeen2026-07-30T00:00:00.000ZTrial by Fire: Uncertainty and Adaptive Management in Forest Ecologyhttps://www.pharmaradar360.com/article/comparing-research-priorities-and-approaches-in-appalachia-and-broader-rural-hea-3f536c3a34c76336Pharma Surgeen2026-07-30T00:00:00.000ZComparing research priorities and approaches in Appalachia and Broader Rural Health Contexts: A Scoping reviewhttps://www.pharmaradar360.com/article/recategorizing-sc-ctsi-s-online-educational-library-using-joint-task-force-core-e631bb3e4b1ea7c8Pharma Surgeen2026-07-30T00:00:00.000ZRecategorizing SC CTSI’s Online Educational Library Using Joint Task Force Core Competencies for Research Professionals: Outlining the Process and Lessons Learnedhttps://www.pharmaradar360.com/article/programmable-multi-stimuli-photonic-hydrogels-for-intelligent-and-adaptive-trans-995d27f838d97b82Pharma Surgeen2026-07-30T00:00:00.000ZProgrammable multi-stimuli photonic hydrogels for intelligent and adaptive transdermal drug deliveryhttps://www.pharmaradar360.com/article/addressing-the-forgotten-dimension-protocol-for-a-convergent-mixed-methods-study-bc8b32e5df34205dPharma Surgeen2026-07-30T00:00:00.000ZAddressing the Forgotten Dimension: Protocol for a Convergent Mixed-methods Study of Sexual Health in Neurological Rehabilitation Patients and Their Care Teamhttps://www.pharmaradar360.com/article/serum-neurofilament-light-protein-as-a-biomarker-across-the-cognitive-decline-co-b37bb8db3f36734cPharma Surgeen2026-07-30T00:00:00.000ZSerum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohorthttps://www.pharmaradar360.com/article/simulation-based-predictions-to-support-the-development-of-a-pediatric-fixed-dos-318dc50acc5a4fbcPharma Surgeen2026-07-30T00:00:00.000ZSimulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumaratehttps://www.pharmaradar360.com/article/surface-engineered-graphitic-carbon-nitride-nanoparticles-for-breast-cancer-ther-92a978c45bc3d024Pharma Surgeen2026-07-30T00:00:00.000ZSurface-engineered graphitic carbon nitride nanoparticles for breast cancer therapy: advances in drug delivery and therapeutic responsehttps://www.pharmaradar360.com/article/midodrine-associated-posterior-reversible-encephalopathy-syndrome-following-medu-6b6f745b543ff565Pharma Surgeen2026-07-30T00:00:00.000ZMidodrine‐Associated Posterior Reversible Encephalopathy Syndrome Following Medullary and Cervical Spinal Cord Infarction in a Childhttps://www.pharmaradar360.com/article/lack-of-differences-in-the-pharmacokinetics-of-therapeutic-monoclonal-antibodies-fb71f9ff8b591a86Pharma Surgeen2026-07-30T00:00:00.000ZLack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individualshttps://www.pharmaradar360.com/article/first-in-human-study-of-a-long-acting-glp-1-receptor-agonist-te-8105-in-overweig-8efa51cce3bb84cbPharma Surgeen2026-07-30T00:00:00.000ZFirst‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitushttps://www.pharmaradar360.com/article/comment-on-survival-improvement-with-steroid-use-for-pulmonary-veno-occlusive-di-6c3e69e4692a8e77Pharma Surgeen2026-07-30T00:00:00.000ZComment on “Survival Improvement With Steroid Use for Pulmonary Veno‐Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine‐Kinase Inhibitor, a Retrospective Study”https://www.pharmaradar360.com/article/nct07738042-to-explore-a-single-arm-phase-ii-study-on-intestinal-microbiota-tran-ea7e713e07c5f228Pharma Surgeen2026-07-30T00:00:00.000ZNCT07738042: To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMRhttps://www.pharmaradar360.com/article/nct07737925-lux-xaluritamig-in-participants-with-metastatic-castrate-resistant-p-d3013dee1bc77f2ePharma Surgeen2026-07-30T00:00:00.000ZNCT07737925: LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetanhttps://www.pharmaradar360.com/article/nct07737834-clinical-radiographic-and-volumetric-evaluation-of-the-entire-papill-4ef426420d59176dPharma Surgeen2026-07-30T00:00:00.000ZNCT07737834: Clinical, Radiographic and Volumetric Evaluation of the Entire Papilla Preservation Technique With and Without Connective Tissue Graft in the Treatment of Periodontal Intraosseous Defects.https://www.pharmaradar360.com/article/nct07737587-yoga-based-breathing-exercises-in-a-salt-cave-environment-versus-a-s-a3fbee05e56cefc6Pharma Surgeen2026-07-30T00:00:00.000ZNCT07737587: Yoga-Based Breathing Exercises in a Salt-Cave Environment Versus a Standard Clinical Setting in Smokershttps://www.pharmaradar360.com/article/nct07737561-blood-pressure-response-to-exercise-and-aortic-stiffness-in-patients-160c88c84816eda2Pharma Surgeen2026-07-30T00:00:00.000ZNCT07737561: Blood Pressure Response to Exercise and Aortic Stiffness in Patients With Cardiovascular-Kidney-Metabolic Syndromehttps://www.pharmaradar360.com/article/nct07736755-blended-learning-for-patient-safety-education-in-nursing-and-midwife-ad424da801bd2b32Pharma Surgeen2026-07-30T00:00:00.000ZNCT07736755: Blended Learning for Patient Safety Education in Nursing and Midwifery Studentshttps://www.pharmaradar360.com/article/nct07736443-effective-implementation-control-trial-107645cb2d3afdcePharma Surgeen2026-07-30T00:00:00.000ZNCT07736443: Effective Implementation Control Trialhttps://www.pharmaradar360.com/article/nct07736417-effects-of-core-stabilization-exercises-on-postural-control-in-spast-aabc1209b39989d8Pharma Surgeen2026-07-30T00:00:00.000ZNCT07736417: Effects of Core Stabilization Exercises on Postural Control in Spastic Diplegic CP Children: a Randomized Control Trialhttps://www.pharmaradar360.com/article/nct07735611-robotic-systems-evaluation-for-peripheral-pulmonary-lesions-rise-tri-6a627da68ea89b97Pharma Surgeen2026-07-30T00:00:00.000ZNCT07735611: Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)https://www.pharmaradar360.com/article/nct07726732-b4b-evolution-type-ii-hybrid-effectiveness-implementation-trial-d923a790c002dfb2Pharma Surgeen2026-07-30T00:00:00.000ZNCT07726732: B4B Evolution Type II Hybrid Effectiveness-Implementation Trial